Skip to main content
. Author manuscript; available in PMC: 2014 May 16.
Published in final edited form as: Obesity (Silver Spring). 2013 Jun 25;21(9):E520–E526. doi: 10.1002/oby.20459

Table 1.

Characteristics of DPP study participants included in these analyses (N=3,891)

Baseline Characteristic Lifestyle Metformin Placebo Troglitazonea P-value
N 1079 1073 1082 585
Male 32% 34% 31% 34% 0.404
Age (years) 51 (11) 51 (10) 50 (10) 50 (10) 0.469
Weight (kg) 94 (21) 94 (20) 94 (20) 93 (19) 0.774
BMI (kg/m2) 34 (7) 34 (7) 34 (7) 34 (6) 0.311
Waist circumference (cm) 105 (15) 105 (14) 105 (14) 104 (14) 0.605
SAT L2-3 (cm2) 308 (125) 301 (129) 314 (127) 0.449
SAT L4-5 (cm2) 443 (152) 433 (154) 449 (151) 0.408
VAT L2-3 (cm2) 200 (85) 195 (83) 199 (90) 0.701
VAT L4-5 (cm2) 163 (65) 158 (65) 159 (65) 0.500
LTPA (MET-hrs/wk) 16 (22) 16 (26) 17 (29) 15 (16) 0.390
Energy Intake (kcal/day) 2137 (1071) 2144 (986) 2098 (1052) 2118 (989) 0.739
Short-term(6m) weight loss(kg) 6.7 (5.6) 2.3 (4.0) 0.3 (4.0) <0.001
Long-term(2y) weight loss(kg) 5.4 (7.6) 2.1 (5.7) 0.0 (5.5) <0.001
Diabetes Incidence per 1,000 p-yr 50 80 100 74 <0.001

Data are percentage or Mean (SD), stratified by treatment assignment. P-values from ANOVA F-tests and Chi-Square test of independence. LTPA: leisure-time physical activity. The sample size (N=3,819) is the maximum number used in baseline analyses and includes participants who were subsequently randomized to troglitazone treatment, in addition to those randomized to lifestyle, metformin, or placebo. Sample sizes for: short-term weight loss (n=3085); long-term weight loss (n=3015); diabetes risk (n=3234). We include individuals subsequently randomized to troglitazone in the baseline analyses to maximize statistical power. However, these individuals are not included in the prospective analyses as they represent a relatively small subgroup of the DPP population, which is likely underpowered for treatment stratified analyses.

a

The troglitazone arm was terminated early(11) and, by consequence, only baseline data are used in this paper.

HHS Vulnerability Disclosure